Immune checkpoint blockade opens an avenue of cancer immunotherapy with a potent clinical efficacy

E-ISSN： 1349-7006|106|8|945-950

ISSN： 1347-9032

Source： Cancer Science, Vol.106, Iss.8, 2015-08, pp. : 945-950

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Lymphocyte‐activation gene‐3, an important immune checkpoint in cancer

Cancer Science, Vol. 107, Iss. 9, 2016-09 ,pp. : 1193-1197

John Wiley & Sons Inc

Access to resources Recommend Favorite

2015 Guidance on cancer immunotherapy development in early‐phase clinical studies

Cancer Science, Vol. 106, Iss. 12, 2015-12 ,pp. : 1761-1771

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical significance of tumor‐infiltrating immune cells focusing on BTLA and Cbl‐b in patients with gallbladder cancer

Cancer Science, Vol. 106, Iss. 12, 2015-12 ,pp. : 1750-1760

John Wiley & Sons Inc

Access to resources Recommend Favorite

Newcastle disease virus co‐expressing interleukin 7 and interleukin 15 modified tumor cells as a vaccine for cancer immunotherapy

Cancer Science, Vol. 109, Iss. 2, 2018-02 ,pp. : 279-288

John Wiley & Sons Inc

Access to resources Recommend Favorite

Cancer immunotherapy using novel tumor‐associated antigenic peptides identified by genome‐wide cDNA microarray analyses

Cancer Science, Vol. 106, Iss. 5, 2015-05 ,pp. : 505-511

John Wiley & Sons Inc

Access to resources Recommend Favorite